This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Layoffs Continue to Mount

ABBOT LABORATORIES

Abbott Laboratories (ABT) plans to lay off 700 workers amid a decline in heart stent orders. Most of the cuts come from the company's heart stents and diagnostic tests business.

Boston Scientific, which pays a 40% royalty on sales of Abbott's Xience stent, recently chose to use Promus Element, its own in-house stent, instead.

Some 300 workers at Abbott's stent business in Southern California will be let go. Less 200 workers will get cut from the diagnostic business in Lake Country, Illinois. The layoffs come as the company has been in ongoing restructuring efforts for years. In early 2010, Abbott cut 1,900 workers in its pharmaceutical division.

The medical device and drug maker reported that its profit increased 12% in the fourth quarter, helped by double digit sales growth of Humira, an anti-inflammatory drug. The braded drug business, which includes Humira, will be spun off so that investors can separately value Abbott's other businesses, according to the company in October. The company's business post-split will be more predictable in that it will be free of risks associated with developing innovative pharmaceutical drugs.

11 of 20

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AVP $8.66 -0.92%
ATV $0.80 -2.20%
HP $74.03 0.53%
IBM $166.16 3.42%
PEP $96.50 0.72%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs